Share

January 14, 2020; 94 (2) Editorial

Putting value back into the “V” of wRVU

William D. Gaillard, Howard P. Goodkin
First published December 24, 2019, DOI: https://doi.org/10.1212/WNL.0000000000008796
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
674

Share

Article Information

vol. 94 no. 2 57-58
DOI: 
https://doi.org/10.1212/WNL.0000000000008796
PubMed: 
31874924
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 24, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. William D. Gaillard, MD and
    2. Howard P. Goodkin, MD, PhD
  1. William D. Gaillard, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate editor Epilepsy Research

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. My income derives form clinical care of patients with epilepsy including EEG, and vEEG

    Clinical procedures or imaging studies:

    1. My income derives from the evaluation and management of children with epilepsy. the institution I work for bills for and collects the proceeds from this evaluation. routine lab fees and imaging fees do not come to my department, but EEG fees do come to my department.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1P30HD40677-01 (PI. V. Gallo, PhD) 8/1/06- 11/30/16 (refunded 12/1/16-11/30/21) NIH, NICHD - IDDRC at Children’s National Medical Center. The main goal of this project is the operation of a center of excellence for research and training in the area of mental retardation and developmental disabilities in Washington, D.C. I direct the imaging core for this project. William D Gaillard, MD: Associate Director IDDRC & Director Image Core PCORnet (PI Brandy Furman PhD) 2/1/18 -1/31/20 Learning Healthcare System Network Collaborative The goal of the project is to build a learning healthcare system for epilepsy as part of national efforts to promote and build learning health care systems. This grant is a partnership between the existing pediatric epilepsy learning healthcare system (PELHS), the Epilepsy Foundation, linked to adult epilepsy efforts. WD Gaillard Co-Investigator. RO1 imaging reorganization of language in perinatal stroke R21 Imaging febrile status epilepsticus

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. BAND Foundation (PI: WD Gaillard MD) 4/14/15-10/30/18 Modifying Epilepsy Related Co-morbidity and Mortality Risk Through Education and Improved Standardization of Care. The goal of this project is to evaluate understanding of mortality and comorbidities among primary care medical personnel, neurology medical personnel and families and to implement education strategies to improve care and education. WD Gaillard PI PERF (PI Kelly Knupp) 8/1/16-7/30/19 A Novel Approach to Infantile Spasms: Combined ACTH and Vigabatrin Induction Therapy The aim of this project is to test the hypothesis that combination therapy with ACTH and VGV is superior to either treatment alone for infants with infantile spasms WD Gaillard Co-Investigator PERF (PI Z Grinspan) 9/1/17-8/30/19 A Learning Healthcare System for Pediatric Epilepsy. This proposal will builds a foundation for ongoing epilepsy research by creating computable phenotypes for subtypes of pediatric epilepsy and creating common data elements for data collection at the point of care. WD Gaillard Co-Investigator American Heart Association. (PI E Newport) 7/1/17-6/30/19 Language, neural reorganization, and functional outcomes after perinatal stroke. This project seeks to examine the reorganization of left and right sided language functions in the setting of perinatal left MCA stroke and characterize functional outcomes in relation to lesion characteristics to illuminate the principles underlying developmental plasticity for Language. WD Gaillard Co-Investigator. Stock/Stock Options, Medical Equipment & Materials: Stock: Johnson and Johnson; Lily, Glaxo-Smith-Kline, Pfizer, General Electric, Siemens

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Howard P. Goodkin, MD, PhD
    3. Scientific Advisory Boards:

    1. (1) Tuberous Sclerois Alliance Scientific Advisory Board (non-profit) Have received no compensation and not relevant to this presentation.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I served on the editorial board of Neurology for 2009- 2016. I currently serve on the editorial board of Annals of Neurology, and Pediatric Neurology. I am currently an Associate Editor of Epilepsy Research.

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) I receive a royalty from Up-to-Date for co-authorship of an entry titled the Choking Game (2) I receive a royalty for the textbook Epilepsy published by John Wiley & Sons

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I was (2016) a member of the clinical standardization team for Sage Therapeutics.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I was a PI on NIH grant NS067439 (2009-2015). I do currently received a small percent effort as a consultant on one NIH grant.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (W.D.G.), Children's National Health System, George Washington University School of Medicine, Washington, DC; and Department of Neurology and Pediatrics (H.P.G.), UVA Health, University of Virginia School of Medicine, Charlottesville.
  1. Correspondence
    Dr. Goodkin Hpg9v{at}virginia.edu
View Full Text

Article usage

Article usage: December 2019 to December 2022

AbstractFullPdfSource
Dec 2019182021Highwire
Jan 2020568313116Highwire
Feb 202027766Highwire
Mar 2020115137Highwire
Apr 202006718Highwire
May 202008216Highwire
Jun 202013325Highwire
Jul 202002924Highwire
Aug 202003318Highwire
Sep 202024332Highwire
Oct 202083825Highwire
Nov 202012711Highwire
Dec 202022019Highwire
Jan 202101524Highwire
Feb 202121927Highwire
Mar 202102118Highwire
Apr 202102814Highwire
May 20211146Highwire
Jun 20211207Highwire
Jul 20213116Highwire
Aug 202112711Highwire
Sep 20211116Highwire
Oct 20210935Highwire
Nov 202101617Highwire
Dec 20210154Highwire
Jan 20220102Highwire
Feb 20220155Highwire
Mar 20220189Highwire
Apr 20223163Highwire
May 20221209Highwire
Jun 20220103Highwire
Jul 20220154Highwire
Aug 2022086Highwire
Sep 20220615Highwire
Oct 2022076Highwire
Nov 20220137Highwire
Dec 2022052Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me